Regulation & law · 26/10/2021

National Cancer Institute to Grant Exclusive Patent License for CRISPR-Engineered T Cell Therapies to Neogene Therapeutics

The National Cancer Institute, part of the National Institutes of Health, Department of Health and Human Services, is considering granting an exclusive patent license to Neogene Therapeutics, Inc., a biotech company based in Santa Monica, CA, to develop and commercialize CRISPR-engineered T cell therapies for cancer treatment.